The rare disease pharmaceutical sector is experiencing an unprecedented boom in Prader-Willi syndrome (PWS) therapeutic innovation. While Soleno’s VYKAT XR has opened new treatment possibilities, a robust pipeline of competing therapies is emerging that could fundamentally alter the therapeutic landscape for this complex genetic disorder. The Evolving PWS Treatment Paradigm Prader-Willi syndrome affects approximately 1 Read.